business information
I upgrade GPCR to Strong Buy, citing compelling fundamentals, and M&A potential, but highlight significant execution, safety, and competitive risks. Structure Therapeutics Inc. (GPCR) is advancing its GLP-1 pill, aleniglipron, into a Phase 3 program. I last covered the stock immediately following…
Business
I rate FAC a Sell, as current price far exceeds probability-weighted scenario value, despite promising tech. Factorial Energy (FAC) has started to trade on the Nasdaq on June 8th after completing its merger with Cartesian Growth Corporation III, in a SPAC IPO, and the stock has nearly doubled from…
Роль токенизированных казначейских облигаций, стейблкоинов и протоколов децентрализованного финансирования в трансформации торгового финансирования. Практические примеры компании Edenex.
